Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cilengitide

Next Previous
X
Search
Drug Profile

Cilengitide

Alternative Names: Cilcane; EMD-121974; EMD-85189; ICE1

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck KGaA; The Scripps Research Institute; University of Munich
  • Developer Iceni Pharmaceuticals; Martin Luther University of Halle-Wittenberg; Merck KGaA; National Cancer Institute (USA)
  • Class Antineoplastics; Cyclic peptides; Small molecules; Venoms
  • Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple myeloma
  • Discontinued Glioblastoma; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 28 Jun 2020 No recent reports of development identified for preclinical development in Multiple-myeloma in United Kingdom
  • 25 May 2016 Preclinical trials in Multiple myeloma in United Kingdom (unspecified route)
  • 25 May 2016 Iceni Pharmaceuticals plans a phase II trial for Multiple myeloma (Combination therapy, Late-stage disease)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top